These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22425989)

  • 1. The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells.
    Du GQ; Zhou L; Chen XY; Wan XP; He YY
    Biochem Biophys Res Commun; 2012 Apr; 420(2):343-9. PubMed ID: 22425989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
    Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
    Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells.
    Vivacqua A; Romeo E; De Marco P; De Francesco EM; Abonante S; Maggiolini M
    Breast Cancer Res Treat; 2012 Jun; 133(3):1025-35. PubMed ID: 22147081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway.
    He YY; Cai B; Yang YX; Liu XL; Wan XP
    Cancer Sci; 2009 Jun; 100(6):1051-61. PubMed ID: 19432902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
    Wei Y; Zhang Z; Liao H; Wu L; Wu X; Zhou D; Xi X; Zhu Y; Feng Y
    Oncol Rep; 2012 Feb; 27(2):504-10. PubMed ID: 22075757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα).
    Tsai CL; Wu HM; Lin CY; Lin YJ; Chao A; Wang TH; Hsueh S; Lai CH; Wang HS
    PLoS One; 2013; 8(9):e72999. PubMed ID: 24039841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells.
    Ignatov A; Ignatov T; Roessner A; Costa SD; Kalinski T
    Breast Cancer Res Treat; 2010 Aug; 123(1):87-96. PubMed ID: 19911269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.
    Ge X; Guo R; Qiao Y; Zhang Y; Lei J; Wang X; Li L; Hu D
    Int J Gynecol Cancer; 2013 Jan; 23(1):52-9. PubMed ID: 23235274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.
    Sakamoto T; Eguchi H; Omoto Y; Ayabe T; Mori H; Hayashi S
    Mol Cell Endocrinol; 2002 Jun; 192(1-2):93-104. PubMed ID: 12088871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30.
    Vivacqua A; Bonofiglio D; Albanito L; Madeo A; Rago V; Carpino A; Musti AM; Picard D; Andò S; Maggiolini M
    Mol Pharmacol; 2006 Oct; 70(4):1414-23. PubMed ID: 16835357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between estrogen receptor and mitogen-activated protein kinase signaling in the development and progression of endometrial cancer.
    Zhou L; Cai B; Bao W; He YY; Chen XY; Yang YX; Liu XL; Wan XP
    Int J Gynecol Cancer; 2011 Nov; 21(8):1357-65. PubMed ID: 21720253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2.
    He YY; Du GQ; Cai B; Yan Q; Zhou L; Chen XY; Lu W; Yang YX; Wan XP
    J Cancer Res Clin Oncol; 2012 May; 138(5):775-83. PubMed ID: 22270964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.
    Girgert R; Emons G; Gründker C
    Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Hydroxytamoxifen-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.
    Li Y; Chen Y; Zhu ZX; Liu XH; Yang L; Wan L; Lei TW; Wang XD
    Toxicology; 2013 Jul; 309():61-5. PubMed ID: 23624423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: A retrospective study and an in vitro study.
    Zhang L; Li Y; Lan L; Liu R; Wu Y; Qu Q; Wen K
    Mol Cell Endocrinol; 2016 Dec; 437():51-61. PubMed ID: 27519631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of GPR30 in endometrial pathology after tamoxifen for breast cancer.
    Ignatov T; Eggemann H; Semczuk A; Smith B; Bischoff J; Roessner A; Costa SD; Kalinski T; Ignatov A
    Am J Obstet Gynecol; 2010 Dec; 203(6):595.e9-16. PubMed ID: 20965484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.
    Block M; Fister S; Emons G; Seeber S; Gründker C; Günthert AR
    Anticancer Res; 2010 Jun; 30(6):2025-31. PubMed ID: 20651347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.
    Lin BC; Suzawa M; Blind RD; Tobias SC; Bulun SE; Scanlan TS; Ingraham HA
    Cancer Res; 2009 Jul; 69(13):5415-23. PubMed ID: 19549922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro cytotoxicity of 4'-OH-tamoxifen and estradiol in human endometrial adenocarcinoma cells HEC-1A and HEC-1B.
    Cuevas ME; Lindeman TE
    Oncol Rep; 2015 Jan; 33(1):464-70. PubMed ID: 25351552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.